Drug intelligence / Profile preview

CKD-391

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CKD-391 is an investigational oral pharmaceutical drug developed for the treatment of dyslipidemia, specifically primary hypercholesterolemia and familial hypercholesterolemia. It is being evaluated in phase 3 clinical trials for its efficacy and safety in patients with these conditions. The drug is part of ChongKunDang's pipeline targeting lipid disorders, but its precise mechanism of action has not been publicly disclosed. Clinical studies have involved adult patients with primary hypercholesterolemia, assessing CKD-391 as monotherapy or in combination regimens[1][2][5].

Beyond the preview

Go deeper on CKD-391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-391.

Explore the full profile